{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:12:13Z","timestamp":1781712733676,"version":"3.54.5"},"reference-count":24,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Preclinical data demonstrated that combining an anti\u2013programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were \u226518 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3\u00a0weeks plus dinaciclib 7 mg\/m2 on day 1 and 10 mg\/m2 on day 8 of cycle 1 and 14 mg\/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received \u22651 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5\/17, rrCLL), 21.1% (8\/38, rrDLBCL), and 0% (0\/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti\u2013PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005872","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T21:01:14Z","timestamp":1640984474000},"page":"1232-1242","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0682","authenticated-orcid":false,"given":"Gareth P.","family":"Gregory","sequence":"first","affiliation":[{"name":"Department of Hematology, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Henry Ford Cancer Institute, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, UT Health San Antonio, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peninsula Health and Peninsula Private Hospitals, Frankston, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-9793","authenticated-orcid":false,"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Division of Oncology, Johns Hopkins Medical Institution, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Escobar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Texas Oncology\u2013Baylor Charles A. Sammons Cancer Center, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-644X","authenticated-orcid":false,"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[{"name":"Section of Hematologic Malignancies, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-7543","authenticated-orcid":false,"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Columbia University Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Wisconsin Carbone Cancer Center, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-5804","authenticated-orcid":false,"given":"Witold","family":"Rybka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Medical Oncology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mohrbacher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-7525","authenticated-orcid":false,"given":"Mo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marinello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"2022021616292963000_B1","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Version 1.2021. Chronic Lymphocytic leukemia\/Small Lymphocytic Lymphoma","author":"National Comprehensive Cancer Network","year":"2020"},{"issue":"1","key":"2022021616292963000_B2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J Hematol Oncol."},{"issue":"6","key":"2022021616292963000_B3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expert Opin Investig Drugs."},{"issue":"8","key":"2022021616292963000_B4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/leu.2015.99","article-title":"Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1","volume":"29","author":"Li","year":"2015","journal-title":"Leukemia."},{"issue":"6","key":"2022021616292963000_B5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/leu.2015.10","article-title":"CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in\u00a0vivo","volume":"29","author":"Gregory","year":"2015","journal-title":"Leukemia."},{"issue":"2","key":"2022021616292963000_B6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI94586","article-title":"Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression","volume":"128","author":"Hossain","year":"2018","journal-title":"J Clin Invest."},{"issue":"14","key":"2022021616292963000_B7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"34","key":"2022021616292963000_B8","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022021616292963000_B9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia."},{"issue":"4","key":"2022021616292963000_B10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","article-title":"Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias","volume":"72","author":"Gojo","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"2022021616292963000_B11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood."},{"issue":"21","key":"2022021616292963000_B12","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1182\/blood.V116.21.3966.3966","article-title":"Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (sch 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients","volume":"116","author":"Baiocchi","year":"2010","journal-title":"Blood."},{"issue":"10","key":"2022021616292963000_B13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood."},{"issue":"14","key":"2022021616292963000_B14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","article-title":"Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials","volume":"31","author":"Ji","year":"2013","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022021616292963000_B15","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2022021616292963000_B16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022021616292963000_B17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma [published corrections appear in Leukemia. 2006;20(12):2220 and 2007;21(5):1134]","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia."},{"issue":"3","key":"2022021616292963000_B18","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol."},{"issue":"9","key":"2022021616292963000_B19","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"issue":"9","key":"2022021616292963000_B20","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"issue":"3","key":"2022021616292963000_B21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia."},{"issue":"33","key":"2022021616292963000_B22","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase ii checkmate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol."},{"issue":"21","key":"2022021616292963000_B23","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022021616292963000_B24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1232\/1871811\/advancesadv2021005872.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1232\/1871811\/advancesadv2021005872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T08:12:03Z","timestamp":1674288723000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/4\/1232\/483296\/Pembrolizumab-plus-dinaciclib-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005872","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}